The FDA on April 28, 2014 approved PURIXAN® for the treatment of patients with Acute Lymphoblastic Leukemia (ALL) as part of a combination regimen. PURIXAN® oral suspension is a product of NOVA Laboratories Limited.
Bottom Ad
Advertisement
Subscribe
